- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00312832
Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy
A Randomized Open Label Study Comparing the Impact of Reducing the Dose of Stavudine Versus Switching to Tenofovir on Plasma Lipids, Body Composition and Mitochondrial Function in HIV-Infected Patients Receiving Antiretroviral Therapy
Background: Stavudine-containing regimens are associated with a potential for lipoatrophy and dyslipidemia. We assessed the safety and efficacy of reducing the dose of stavudine compared to switching to tenofovir or maintaining the standard dose of stavudine.
Methods: Clinically stable lipoatrophic HIV-infected patients receiving antiretroviral therapy containing stavudine 40 mg bid with a plasma HIV RNA <200 copies/mL for at least 6 months were randomized to maintain stavudine 40 mg bid (d4T40 arm), to reduce to 30 mg bid (d4T30 arm), or to switch from stavudine to tenofovir-DF (TDF arm) while preserving the remaining drugs. Fasting metabolic parameters were assessed at baseline and at weeks 4, 12, and 24. Mitochondrial parameters in peripheral blood mononuclear cells and body composition were measured at baseline and at week 24.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Study eligibility criteria included documented HIV infection, age 18 years or older, moderate to severe clinical lipoatrophy in at least one region upon physical examination (17,18), viral load <200 copies/mL for at least 6 months prior to inclusion in the study, and a stable triple antiretroviral therapy including d4T 40 mg bid for at least the 6 preceding months, and no prior TDF use.
Exclusion Criteria:
Prior TDF use, viral load>200 copies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jose Maria Gatell, Hospital Clinic of Barcelona
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Skin Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Lipid Metabolism Disorders
- Skin Diseases, Metabolic
- HIV Infections
- Lipodystrophy
Other Study ID Numbers
- D40-30
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on switching; dose reduction
-
Medical University of South CarolinaNational Cancer Institute (NCI)RecruitingTreatment | Cigarette Smoking | Smoking BehaviorsUnited States
-
McMaster UniversityCanadian Frailty Network; Labarge Optimal AgingTerminatedFrailty | Polypharmacy | Long-term CareCanada
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); David Braley and Nancy Gordon... and other collaboratorsRecruitingPolypharmacy | Multi-morbidity | Medication Therapy ManagementCanada
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); David Braley and Nancy Gordon... and other collaboratorsRecruitingPolypharmacy | Multi-morbidity | Medication Therapy ManagementCanada
-
Universitaire Ziekenhuizen KU LeuvenCompleted
-
University of MinnesotaNot yet recruitingAdaptive Behavior | Perception of Things Changing ColorUnited States
-
McMaster UniversityHealth Canada; David Braley and Nancy Gordon Chair in Family Medicine; RxISK; The...CompletedMedication Therapy Management | ComorbidityCanada
-
The Netherlands Cancer InstituteUnknownMyxoid Liposarcoma of Soft TissueNetherlands, United Kingdom, Norway, United States, Denmark
-
Kafrelsheikh UniversityCompletedPeri-implant Mucositis | Dental Implant FailedEgypt
-
Ospedali Riuniti AnconaThe University of Hong Kong; Yale University; The Leeds Teaching Hospitals NHS...Withdrawn